AR051009A1 - Formulaciones de estabilizacion de proteinas - Google Patents
Formulaciones de estabilizacion de proteinasInfo
- Publication number
- AR051009A1 AR051009A1 ARP050103456A ARP050103456A AR051009A1 AR 051009 A1 AR051009 A1 AR 051009A1 AR P050103456 A ARP050103456 A AR P050103456A AR P050103456 A ARP050103456 A AR P050103456A AR 051009 A1 AR051009 A1 AR 051009A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- formulation
- suffractant
- storing
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Las formulaciones descritas son adecuadas para el almacenamiento de proteínas, tal como los anticuerpos, sobre, relativamente, una escala ancha de concentraciones de proteínas, pH, y tipos de tampones. También están descritos los métodos de almacenar una proteína y métodos de identificación de una formulación adecuada para el almacenamiento de una proteína específica. En general, una formulación contiene una cantidad baja o ningún sufractante, nada o una concentración relativamente baja de sal, y requiere e una concentración baja de tampón. Reivindicación 1: Una formulación incluyendo (a) una proteína aislada; y (b) una solución acuosa que tiene un pH de 4.0 a pH 8.0, en qué la formulación contiene un crioprotectante o sufractante, y la proteína es estable por un período de tiempo de no menos de 3 semanas a una temperatura entre -80°C a 8°C. Reivindicación 49: Un polipéptido producido por un método que incluye almacenamiento en una formulación de la afirmación 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60131104P | 2004-08-13 | 2004-08-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR051009A1 true AR051009A1 (es) | 2006-12-13 |
Family
ID=35908214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050103456A AR051009A1 (es) | 2004-08-13 | 2005-08-16 | Formulaciones de estabilizacion de proteinas |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8871201B2 (es) |
| EP (1) | EP1784219B1 (es) |
| JP (1) | JP4948407B2 (es) |
| KR (1) | KR20070092197A (es) |
| CN (1) | CN101022831A (es) |
| AR (1) | AR051009A1 (es) |
| AU (1) | AU2005272603A1 (es) |
| BR (1) | BRPI0514340A (es) |
| CA (1) | CA2575870A1 (es) |
| CR (1) | CR8904A (es) |
| EC (1) | ECSP077246A (es) |
| ES (1) | ES2637854T3 (es) |
| IL (1) | IL181265A0 (es) |
| MX (1) | MX2007001599A (es) |
| NO (1) | NO20070930L (es) |
| RU (1) | RU2007109062A (es) |
| TW (1) | TW200621282A (es) |
| WO (1) | WO2006020935A2 (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| CA2610839C (en) | 2005-06-14 | 2019-06-25 | Amgen Inc. | Self-buffering protein formulations |
| CA2649538C (en) * | 2006-04-21 | 2014-06-03 | Yatin Gokarn | Buffering agents for biopharmaceutical formulations |
| EA018301B1 (ru) | 2006-04-21 | 2013-07-30 | Новартис Аг | Фармацевтические композиции, содержащие антагонистическое моноклональное антитело к cd40, и их применение |
| US20080070230A1 (en) * | 2006-06-12 | 2008-03-20 | Wyeth | Methods for reducing or preventing liquid-liquid phase separation in high concentration protein solutions |
| EP1950225A1 (de) * | 2007-01-25 | 2008-07-30 | Octapharma AG | Verfahren zur Steigerung von Proteinausbeuten |
| CN101679507A (zh) | 2007-03-29 | 2010-03-24 | 艾博特公司 | 结晶抗人类il-12抗体 |
| KR20150080038A (ko) * | 2007-11-30 | 2015-07-08 | 애브비 바이오테크놀로지 리미티드 | 단백질 제형 및 이의 제조방법 |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| CA2742791A1 (en) * | 2008-11-28 | 2010-06-03 | Abbott Laboratories | Stable antibody compositions and methods for stabilizing same |
| US9265834B2 (en) | 2009-03-05 | 2016-02-23 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
| EP2403873A1 (en) | 2009-03-05 | 2012-01-11 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
| CN104490767A (zh) * | 2009-05-04 | 2015-04-08 | 艾伯维生物技术有限公司 | 人抗TNF-α抗体的稳定高蛋白质浓度制剂 |
| ES2617180T3 (es) | 2009-09-03 | 2017-06-15 | Ablynx N.V. | Formulaciones estables de polipéptidos y uso de las mismas |
| CN103930124B (zh) | 2011-07-01 | 2021-05-11 | 生物基因Ma公司 | 无精氨酸的tnfr：fc-融合多肽组合物及使用方法 |
| WO2013082418A1 (en) | 2011-11-30 | 2013-06-06 | 3M Innovative Properties Company | Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| WO2013148686A2 (en) * | 2012-03-26 | 2013-10-03 | Sanofi | Stable igg4 binding agent formulations |
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| WO2014099636A1 (en) * | 2012-12-18 | 2014-06-26 | Merck Sharp & Dohme Corp. | Liquid formulations for an anti-tnf alpha antibody |
| AR098221A1 (es) | 2013-11-04 | 2016-05-18 | Pfizer | Conjugados de anticuerpo anti-efna4-fármaco |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| US20160018406A1 (en) * | 2014-07-21 | 2016-01-21 | Unchained Labs Inc. | Determination of Protein Aggregation from the Concentration Dependence of Delta G |
| EP4039253A1 (en) | 2015-04-29 | 2022-08-10 | Radius Pharmaceuticals, Inc. | Methods of treating cancer |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| IL307435A (en) | 2016-08-18 | 2023-12-01 | Regeneron Pharma | A test to determine concentration-dependent self-interaction |
| MX2019004580A (es) | 2016-10-21 | 2019-08-12 | Amgen Inc | Formulaciones farmaceuticas y metodos para prepararlas. |
| KR20230109795A (ko) | 2017-01-05 | 2023-07-20 | 래디어스 파마슈티컬스, 인코포레이티드 | Rad1901-2hcl의 다형 형태 |
| SG11202013177WA (en) | 2018-07-04 | 2021-01-28 | Radius Pharmaceuticals Inc | Polymorphic forms of rad 1901-2hcl |
| TW202245823A (zh) * | 2021-01-14 | 2022-12-01 | 南韓商韓兀生物製藥股份有限公司 | 無穩定劑或實質上無穩定劑之含有天凡諾賽普特（ｔａｎｆａｎｅｒｃｅｐｔ）的穩定眼用組成物 |
| CN115541895B (zh) * | 2022-11-29 | 2023-05-19 | 天津德祥生物技术股份有限公司 | 一种提高微流控反定检测卡灵敏度的配方液及应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0041768B1 (en) | 1980-04-24 | 1987-11-11 | Beecham Group Plc | Beta-lactam compounds, their preparation and use |
| GB8518416D0 (en) | 1985-07-22 | 1985-08-29 | Beecham Group Plc | Compounds |
| US5869053A (en) * | 1988-03-04 | 1999-02-09 | Cancer Research Campaign Technology, Ltd. | 5T4 antigen from human trophoblasts |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| EP1012259B1 (en) | 1997-06-04 | 2009-09-30 | Oxford Biomedica (UK) Limited | Tumor targeted vector |
| AU740284B2 (en) | 1997-06-13 | 2001-11-01 | Genentech Inc. | Stabilized antibody formulation |
| WO1999037329A1 (en) | 1998-01-22 | 1999-07-29 | Astrazeneca Ab | Pharmaceutical formulation comprising an antibody and a citrate buffer |
| US20030124119A1 (en) * | 1999-12-28 | 2003-07-03 | Tadao Yamazaki | Stable antibody compositions and injection preparations |
| ES2477996T3 (es) | 2000-08-11 | 2014-07-18 | Chugai Seiyaku Kabushiki Kaisha | Preparaciones estabilizadas que contienen un anticuerpo |
| AU1344102A (en) * | 2000-10-12 | 2002-04-22 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
| GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| WO2003057163A2 (en) * | 2002-01-03 | 2003-07-17 | Smithkline Beecham Corporation | Methods for preparing immunoconjugates |
| DK2371392T3 (en) | 2002-05-02 | 2015-08-31 | Wyeth Holdings Llc | Calicheamicin derivative / carrier conjugates |
| AU2003251592A1 (en) * | 2002-06-21 | 2004-01-06 | Biogen Idec Inc. | Buffered formulations for concentrating antibodies and methods of use thereof |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| US20080268459A1 (en) * | 2003-08-14 | 2008-10-30 | Wyeth Ludwig Institute For Cancer | Anti-Lewis Y Anti-Idiotypic Antibodies and Uses Thereof |
| BRPI0515113A (pt) * | 2004-09-10 | 2008-07-01 | Wyeth Corp | anticorpos anti-5t4 humanizados e conjugados de anticorpo anti-5t4/caliqueamicina |
-
2005
- 2005-08-11 TW TW094127308A patent/TW200621282A/zh unknown
- 2005-08-12 RU RU2007109062/13A patent/RU2007109062A/ru not_active Application Discontinuation
- 2005-08-12 US US11/203,367 patent/US8871201B2/en active Active
- 2005-08-12 BR BRPI0514340-3A patent/BRPI0514340A/pt not_active IP Right Cessation
- 2005-08-12 ES ES05803522.1T patent/ES2637854T3/es active Active
- 2005-08-12 MX MX2007001599A patent/MX2007001599A/es unknown
- 2005-08-12 CA CA002575870A patent/CA2575870A1/en not_active Abandoned
- 2005-08-12 KR KR1020077003502A patent/KR20070092197A/ko not_active Application Discontinuation
- 2005-08-12 CN CNA2005800274833A patent/CN101022831A/zh active Pending
- 2005-08-12 WO PCT/US2005/028861 patent/WO2006020935A2/en active Application Filing
- 2005-08-12 JP JP2007525855A patent/JP4948407B2/ja active Active
- 2005-08-12 AU AU2005272603A patent/AU2005272603A1/en not_active Abandoned
- 2005-08-12 EP EP05803522.1A patent/EP1784219B1/en active Active
- 2005-08-16 AR ARP050103456A patent/AR051009A1/es unknown
-
2007
- 2007-02-06 CR CR8904A patent/CR8904A/es not_active Application Discontinuation
- 2007-02-11 IL IL181265A patent/IL181265A0/en unknown
- 2007-02-13 EC EC2007007246A patent/ECSP077246A/es unknown
- 2007-02-19 NO NO20070930A patent/NO20070930L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070092197A (ko) | 2007-09-12 |
| NO20070930L (no) | 2007-05-14 |
| US8871201B2 (en) | 2014-10-28 |
| WO2006020935A3 (en) | 2007-03-08 |
| WO2006020935A2 (en) | 2006-02-23 |
| ES2637854T3 (es) | 2017-10-17 |
| EP1784219A4 (en) | 2010-02-17 |
| ECSP077246A (es) | 2007-05-30 |
| US20060115472A1 (en) | 2006-06-01 |
| BRPI0514340A (pt) | 2008-06-10 |
| CN101022831A (zh) | 2007-08-22 |
| IL181265A0 (en) | 2007-07-04 |
| CA2575870A1 (en) | 2006-02-23 |
| CR8904A (es) | 2007-08-28 |
| JP2008515775A (ja) | 2008-05-15 |
| TW200621282A (en) | 2006-07-01 |
| AU2005272603A1 (en) | 2006-02-23 |
| MX2007001599A (es) | 2007-04-10 |
| EP1784219B1 (en) | 2017-05-17 |
| EP1784219A2 (en) | 2007-05-16 |
| RU2007109062A (ru) | 2008-09-20 |
| JP4948407B2 (ja) | 2012-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR051009A1 (es) | Formulaciones de estabilizacion de proteinas | |
| JP2017222654A5 (es) | ||
| PE20070796A1 (es) | Metodo de produccion proteica utilizando compuestos anti-senescencia | |
| BR102014025328B8 (pt) | Composição herbicida aquosa estável, e método para controle de vegetação indesejável | |
| AR098880A2 (es) | Solución protectora para prevenir daños isquémicos en los órganos o en sistemas celulares aislados o en componentes de tejido después de la perfusión, operación, transplante o crio-conservación y subsiguiente reperfusión | |
| Vadnais et al. | Seminal plasma proteins inhibit in vitro-and cooling-induced capacitation in boar spermatozoa | |
| CO2019011463A2 (es) | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas | |
| PE20081258A1 (es) | ANTICUERPOS ANTI-hTNFALFA CRISTALINOS | |
| SV2006002211A (es) | Produccion de tnfr-ig ref.2004658-0091 | |
| ATE406102T1 (de) | Verfahren zur konservierung von frischen produkte und dafür geeignete überzugsmischung | |
| ES2140444T3 (es) | Composicion y procedimiento para desarrollar viscosidad extensional en composiciones limpiadoras. | |
| Dumorne et al. | Protein phosphorylation and ions effects on salmonid sperm motility activation | |
| Li et al. | Sperm proteins in teleostean and chondrostean (sturgeon) fishes | |
| ES2280924T3 (es) | Composicion liquida biologicamente estable de fviii, de fvw o del complejo fviii/fvw humanos. | |
| RU2004119056A (ru) | Составленные на основе воды фармацевтические композиции водорастворимых пролекарств пропофола | |
| CO5320611A1 (es) | Una composicion para extraer sales metalicas divalentes, un metodo para prepararla y su uso para reducir los depositos de sales metalicas divalentes en un sistema acuoso | |
| Kowalski et al. | Effect of albumin and casein supplementation on the common carp Cyprinus carpio L. sperm motility parameters measured by CASA | |
| Lee et al. | Cryopreservation of Korean Oge chicken semen using N-methylacetamide | |
| CO2022005737A2 (es) | Formulación estable de anticuerpo de integrina | |
| ECSP045101A (es) | Metodo para controlar nematodos parasitos de plantas dañinos | |
| Hu et al. | High‐throughput cryopreservation of sperm from sex‐reversed Southern Flounder, Paralichthys lethostigma | |
| CO5601034A2 (es) | Metodos para conservar soluciones oftalmicas y soluciones oftalmicas conservadas | |
| IT1317301B1 (it) | Concentrazioni di saccarosio e durata dell'esposizione dell'ovocita asoluzioni di caricamento nella procedura di crioconservazione di | |
| JP2010091398A (ja) | 安定なナトリウム利尿ペプチド組成物 | |
| Strzeżek et al. | Effect of different egg yolk sources on dog semen quality following cryopreservation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |